Becton, Dickinson and Company (NYSE:BDX) Shares Purchased by Tranquilli Financial Advisor LLC

Tranquilli Financial Advisor LLC raised its stake in Becton, Dickinson and Company (NYSE:BDX) by 72.2% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 3,114 shares of the medical instruments supplier’s stock after acquiring an additional 1,306 shares during the period. Tranquilli Financial Advisor LLC’s holdings in Becton, Dickinson and Company were worth $706,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in BDX. E. Ohman J or Asset Management AB raised its stake in Becton, Dickinson and Company by 13.4% during the 4th quarter. E. Ohman J or Asset Management AB now owns 176,097 shares of the medical instruments supplier’s stock valued at $39,951,000 after purchasing an additional 20,859 shares during the period. RBA Wealth Management LLC increased its stake in shares of Becton, Dickinson and Company by 2.9% during the 4th quarter. RBA Wealth Management LLC now owns 21,331 shares of the medical instruments supplier’s stock worth $4,839,000 after purchasing an additional 604 shares during the last quarter. S.A. Mason LLC raised its holdings in shares of Becton, Dickinson and Company by 3.7% during the 4th quarter. S.A. Mason LLC now owns 1,414 shares of the medical instruments supplier’s stock valued at $321,000 after purchasing an additional 50 shares in the last quarter. Oregon Pacific Wealth Management LLC acquired a new stake in shares of Becton, Dickinson and Company in the 4th quarter valued at $244,000. Finally, U.S. Capital Wealth Advisors LLC grew its holdings in Becton, Dickinson and Company by 14.3% in the 4th quarter. U.S. Capital Wealth Advisors LLC now owns 1,224 shares of the medical instruments supplier’s stock valued at $278,000 after buying an additional 153 shares during the last quarter. 86.97% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of research analysts have commented on BDX shares. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research note on Wednesday, December 18th. Piper Sandler increased their price objective on shares of Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. One investment analyst has rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. According to MarketBeat, Becton, Dickinson and Company has an average rating of “Moderate Buy” and an average price target of $283.00.

Becton, Dickinson and Company Stock Down 0.0 %

Shares of BDX stock opened at $247.57 on Tuesday. The company has a market capitalization of $71.80 billion, a price-to-earnings ratio of 41.68, a P/E/G ratio of 1.80 and a beta of 0.40. Becton, Dickinson and Company has a 12-month low of $218.75 and a 12-month high of $251.99. The firm has a fifty day moving average of $230.53 and a 200-day moving average of $233.83. The company has a quick ratio of 0.74, a current ratio of 1.17 and a debt-to-equity ratio of 0.69.

Becton, Dickinson and Company (NYSE:BDX) last released its quarterly earnings results on Thursday, November 7th. The medical instruments supplier reported $3.81 earnings per share for the quarter, topping analysts’ consensus estimates of $3.77 by $0.04. Becton, Dickinson and Company had a return on equity of 14.89% and a net margin of 8.55%. The firm had revenue of $5.44 billion during the quarter, compared to the consensus estimate of $5.38 billion. During the same quarter in the prior year, the firm posted $3.42 EPS. The business’s revenue was up 6.9% on a year-over-year basis. As a group, equities research analysts predict that Becton, Dickinson and Company will post 14.41 earnings per share for the current fiscal year.

Becton, Dickinson and Company Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be paid a $1.04 dividend. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 dividend on an annualized basis and a yield of 1.68%. Becton, Dickinson and Company’s dividend payout ratio is 70.03%.

Becton, Dickinson and Company announced that its board has authorized a share buyback plan on Tuesday, January 28th that authorizes the company to repurchase 10,000,000 shares. This repurchase authorization authorizes the medical instruments supplier to repurchase shares of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s leadership believes its stock is undervalued.

Insiders Place Their Bets

In other Becton, Dickinson and Company news, EVP David Shan sold 500 shares of the firm’s stock in a transaction on Tuesday, January 21st. The stock was sold at an average price of $240.00, for a total transaction of $120,000.00. Following the transaction, the executive vice president now owns 5,741 shares in the company, valued at $1,377,840. This trade represents a 8.01 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Michael David Garrison sold 597 shares of the company’s stock in a transaction on Friday, January 17th. The shares were sold at an average price of $236.51, for a total value of $141,196.47. Following the sale, the executive vice president now owns 5,544 shares of the company’s stock, valued at approximately $1,311,211.44. The trade was a 9.72 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 9,844 shares of company stock valued at $2,210,716 in the last 90 days. 0.36% of the stock is currently owned by insiders.

Becton, Dickinson and Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.